Stockscreener 앱 받기
8.20
2.12%
0.17
전일 마감가:
$8.03
열려 있는:
$8.05
하루 거래량:
1.44M
Relative Volume:
0.97
시가총액:
$905.79M
수익:
-
순이익/손실:
$-227.05M
주가수익비율:
-3.3065
EPS:
-2.48
순현금흐름:
$-177.93M
1주 성능:
+11.26%
1개월 성능:
+4.59%
6개월 성능:
-4.76%
1년 성능:
+78.65%
1일 변동 폭
$7.7428
$8.24
1주일 범위
$7.7428
$8.72
52주 변동 폭
$4.28
$12.61
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
8.20 | 905.79M | 0 | -227.05M | -177.93M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Assenagon Asset Management S.A. Sells 133,515 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent and ModivCare gain after insider purchases - MSN
How to Take Advantage of moves in (COGT) - Stock Traders Daily
Short Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 9.3% - MarketBeat
Cogent Biosciences Appoints James P. Geygan as Independent Director - Defense World
Hennion & Walsh Asset Management Inc. Buys 103,293 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data - Seeking Alpha
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - Yahoo Finance
Cole Pinnow Bought 2,085% More Shares In Cogent Biosciences - Yahoo Finance
HC Wainwright Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $14.00 - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.83 - Defense World
Cogent Biosciences chief commercial officer buys $332,412 in stock By Investing.com - Investing.com Canada
Cogent stock ModivCare stock up on insider buys (COGT:NASDAQ) - Seeking Alpha
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's What Happened - MarketBeat
Cogent Biosciences chief commercial officer buys $332,412 in stock - Investing.com
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Average Target Price from Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Receives Neutral Rating from Wedbush - Defense World
Wedbush Reiterates Neutral Rating for Cogent Biosciences (NASDAQ:COGT) - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 11.9%Here's Why - MarketBeat
Cogent Biosciences Announces Planned 2025 Milestones for - GlobeNewswire
Cogent Biosciences sets key 2025 milestones for drug trials By Investing.com - Investing.com South Africa
Cogent Biosciences sets key 2025 milestones for drug trials - Investing.com India
Cogent Biosciences Sets Major 2025 Milestones: Three Phase 3 Results, First NDA Submission Planned - StockTitan
Objective long/short (COGT) Report - Stock Traders Daily
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Cogent Biosciences (NASDAQ:COGT) Shares Up 8.8%Still a Buy? - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 2.5%What's Next? - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Holdings Trimmed by Jane Street Group LLC - Defense World
Jane Street Group LLC Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
(COGT) Investment Report - Stock Traders Daily
Geode Capital Management LLC Buys 300,062 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Geode Capital Management LLC Purchases 300,062 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Barclays PLC Boosts Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Barclays PLC Has $1.90 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus Target Price from Analysts - Defense World
State Street Corp Sells 605,500 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat
What is HC Wainwright’s Forecast for COGT FY2024 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for COGT Earnings - MarketBeat
Needham Downgrades Cogent Biosciences (COGT) - MSN
Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):